排序方式: 共有32条查询结果,搜索用时 15 毫秒
1.
生长抑素垂体后叶素及奥美拉唑三联治疗肝硬化食管胃底静脉曲张破裂出血疗效观察 总被引:4,自引:0,他引:4
目的 评价生长抑素、垂体后叶素及奥美拉唑三联治疗肝硬化食管胃底静脉曲张破裂出血的疗效和不良反应.方法 将157例肝硬化并食管胃底静脉曲张破裂出血患者随机分为三组:生长抑素、垂体后叶素及奥美拉唑三联(A)组77例,单用生长抑素(B)组42例及单用垂体后叶素(C)组38例,记录并比较三组药物治疗上消化道出血的疗效及不良反应.结果 A组治疗食管胃底静脉曲张破裂出血有效率93%(72/77),明显高于B组78%(33/42)和C组55%(21/38),P均<0.05.A组药物不良反应发生率为22%,明显低于C组(44%,P<0.05),而与B组差异无统计学意义(14%,P>0.05).结论 生长抑素、垂体后叶素及奥美拉唑三联治疗肝硬化食管胃底静脉曲张破裂出血安全、有效. 相似文献
2.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献
3.
目的 评价干扰素-α1b(赛若金)的抗肝纤维化作用及其与抗病毒疗效的关系。方法 干扰素-α1b治疗57例慢性乙型肝炎患者,对照组用常规方法治疗,检测治疗前后血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN),Ⅳ型胶原(ⅣC)的含量变化。结果 治疗组疗程结束后,HA、PCⅢ、LN和ⅣC均有不同程度下降,血清HBV DNA阴转者降幅显著大于未阴转者,与对照组比较有显著差异(P<0.05)。结论 赛若金可减轻慢性乙型肝炎患者肝纤维化程度,其抗肝纤维化作用与抗病毒作用呈一致关系。 相似文献
4.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献
5.
目的 调查本地区乙型肝炎病毒(HBV)基因分型的分布情况,观察乙型肝炎基因分型对阿德福韦酯抗病毒疗效的影响.方法 对285例慢性乙型肝炎(其中HBV基因型B型219例,C型66例)用阿德福韦酯治疗的慢性乙型肝炎的患者进行分析,观察治疗12周、24周、48周及96周丙氨酸转氨酶(ALT)、HBV DNA定量、乙型肝炎病毒e抗原(HBeAg)乙型肝炎病毒e抗体定量.结果 阿德福韦酯治疗12周时B组以及C组HBV DNA转阴率为30.6%及36.4%,HBV DNA下降均值为(1.36±0.98)eopies/ml及(1.31±1.40)copies/ml(P>0.05);治疗24周两组HBV DNA转阴率分别为33.8%及42.4%,HBV DNA下降均值为(2.19±1.18)copies/ml及(2.22±1.10)copies/ml(P>0.05).治疗48周两组HBV DNA转阴率分别为38.8%及45.5%,HBV DNA下降均值为(2.98±1.24)copies/ml及(2.97±0.92)copies/ml(P>0.05).治疗96周两组HBV DNA转阴率分别为44.8%及48.5%,HBV DNA下降均值为(3.41±1.68)copies/ml及(3.50±1.72)copies/ml(P>0.05).治疗12周后B、C两组HBeAg转阴HBeAb出现分别为10.6%vs 8.6%及11.6%vs 9.3%,24周后B、C两组HBeAg转阴/HBeAb出现分别为14.6%vs 11.3%及16.3%vs 11.6%,48周后B、C两组HBeAg转阴/HBeAb出现分别为27.8%vs 21.2%及25.6%vs 20.9%,96周后B、C两组HBeAg转阴/HBeAb出现分剐为36.4%vs 25.2%及39.5%vs 25.6%,两组差异均无统计学意义(P>0.05).两组ALT复常率12周为59.8%vs 47.0%(P<0.05),24周为60.3%vs 63.6%,48周为76.3%vs 77.3%,96周为80.0%vs 80.3%,两组差异均无统计学意义(P>0.05).结论 阿德福韦酯治疗慢性乙型肝炎B型及C型,病毒应答、生化应答及血清学应答相当,阿德福韦酯时HBV基因B型及C型疗效无明显影响.本地区HBV基因型以B型为主,C型次之,未发现A、D型. 相似文献
6.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献
7.
8.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献
9.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献
10.
Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB. 相似文献